Topotecan

From Wikipedia, the free encyclopedia

Topotecan
Systematic (IUPAC) name
(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-
dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]
quinoline-3,14(4H,12H)-dione monohydrochloride
Identifiers
CAS number 123948-87-8
119413-54-6 (hydrochloride)
ATC code L01XX17
PubChem 6419854
DrugBank APRD00687
Chemical data
Formula C23H23N3O5 •HCl 
Mol. mass 457.9 g/mol
Pharmacokinetic data
Bioavailability NA
Protein binding 35%
Metabolism Hepatic
Half life 2-3 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

D (Au, U.S.)

Legal status

℞-only (U.S.), POM (UK)

Routes Intravenous infusion, oral

Topotecan hydrochloride (trade name Hycamtin) is a chemotherapy agent that is a topoisomerase 1 inhibitor. It is used to treat ovarian cancer and lung cancer, as well as other cancer types.

After GlaxoSmithKline received final FDA approval for Hycamtin Capsules on October 15, 2007, Topotecan is the first topoisomerase inhibitor for oral use.

[edit] Administration

IV, oral.

[edit] Side effects

  • Diarrhea
  • Low blood counts
  • Susceptibility to infection

[edit] External links